Article
Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia.
Blood - 15 Sept 2006
Falini Brunangelo, Martelli Maria Paola, Bolli Niccolò, Bonasso Rossella, Ghia Emanuela, Pallotta Maria Teresa, Diverio Daniela, Nicoletti Ildo, Pacini Roberta, Tabarrini Alessia, Galletti Barbara Verducci, Mannucci Roberta, Roti Giovanni, Rosati Roberto, Specchia Giorgina, Liso Arcangelo, Tiacci Enrico, Alcalay Myriam, Luzi Lucilla, Volorio Sara, Bernard Loris, Guarini Anna, Amadori Sergio, Mandelli Franco, Pane Fabrizio, Lo-Coco Francesco, Saglio Giuseppe, Pelicci Pier-Giuseppe, Martelli Massimo F, Mecucci Cristina
Abstract excerpt
Nucleophosmin (NPM) exon-12 mutations occur in 50% to 60% of adult acute myeloid leukemia (AML) with normal karyotype and are predictors of favorable prognosis. We evaluated bone marrow or peripheral blood samples from 450 adult patients with AML of the GIMEMA (Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto)/AML12 EORTC (European Organization for Research and Treatment of Cancer) trial to (1) search...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
